EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV–Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial

Ran Wang iD, Lijun Sun, Xi Wang, Yuanyi Zhai, Lijing Wang, Ping Ma, Cuisong Wu, Yingquan Zhou, Renfang Chen, Rugang Wang, Fengchi Zhang, Wei Hua und 11 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae012 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Ran Wang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: HIV Infections, Tenofovir, Emtricitabine, Homosexuality, Male. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Beijing Municipal of Science and Technology Major Project, National Natural Science Foundation Program, Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Most international treatment guidelines recommend rapid initiation of antiretroviral therapy (ART) for people newly diagnosed with human immunodeficiency virus (HIV)-1 infection, but experiences with rapid ART initiation remain limited in China. We aimed to evaluate the efficacy and safety of efavirenz (400 mg) plus lamivudine and tenofovir disoproxil fumarate (EFV + 3TC + TDF) versus coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) in rapid ART initiation among men who have sex with men (MSM) who have been diagnosed with HIV.

Methods

This multicenter, open-label, randomized clinical trial enrolled MSM aged ≥18 years to start ART within 14 days of confirmed HIV diagnosis. The participants were randomly assigned in a 1:1 ratio to receive EFV (400 mg) + 3TC + TDF or BIC/FTC/TAF. The primary end point was viral suppression (<50 copies/mL) at 48 weeks per US Food and Drug Administration Snapshot analysis.

Results

Between March 2021 and July 2022, 300 participants were enrolled; 154 were assigned to receive EFV + 3TC + TDF (EFV group) and 146 BIC/FTC/TAF (BIC group). At week 48, 118 (79.2%) and 140 (95.9%) participants in the EFV and BIC group, respectively, were retained in care with viral suppression, and 24 (16.1%) and 1 (0.7%) participant in the EFV and BIC group (P < .001), respectively, discontinued treatment because of adverse effects, death, or lost to follow-up. The median increase of CD4 count was 181 and 223 cells/μL (P = .020), respectively, for the EFV and BIC group, at week 48. The overall incidence of adverse effects was significantly higher for the EFV group (65.8% vs 37.7%, P < .001).

Conclusions

BIC/FTC/TAF was more efficacious and safer than EFV (400 mg) + 3TC + TDF for rapid ART initiation among HIV-positive MSM in China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsTenofovirEmtricitabineHomosexuality, MaleCyclopropanesAnti-HIV AgentsAlkynesLamivudineBenzoxazinesHumansMaleAdultChinaAlanineMiddle AgedHeterocyclic Compounds, 4 or More RingsCD4 Lymphocyte CountDioxolanesHeterocyclic Compounds, 3-RingPiperazinesAntiretroviral Therapy, Highly ActiveViral LoadYoung AdultDrug CombinationsHIV-1AmidesPyridones

Stichwörter der Autor:innen

care cascadeintegrase strand-transfer inhibitornon-nucleoside reverse-transcriptase inhibitortreatment retentiontreatment-as-prevention

Substanzen

TenofovirEmtricitabineCyclopropanesAnti-HIV AgentsAlkynesLamivudineBenzoxazinesefavirenzAlanineHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
  • Shijiazhuang Fifth Hospital, Shijiazhuang, People's Republic of China.
  • Tianjin Second People's Hospital, Tianjin, People's Republic of China.
  • Zhenjiang Third People's Hospital, Zhenjiang, People's Republic of China.
  • Pulmonary Hospital of Lanzhou, Lanzhou, People's Republic of China.
  • Wuxi Fifth People's Hospital, Wuxi, People's Republic of China.

ORCID-Profile: Ran Wang, Lili Dai

Förderung

  • Beijing Municipal of Science and Technology Major Project
  • National Natural Science Foundation Program
  • Beijing Natural Science Foundation
  • High-level Health Talent Construction Project
  • Beijing Youan Hospital Construction of Talent Pool Program

Zitieren

APA

Wang, R., Sun, L., Wang, X., Zhai, Y., Wang, L., Ma, P., Wu, C., Zhou, Y., Chen, R., Wang, R., Zhang, F., Hua, W., Li, A., Xia, W., Gao, Y., Li, R., Lv, S., Shao, Y., Cao, Y., …, & Dai, L. (2024). Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV–Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae012

Vancouver

Wang R, Sun L, Wang X, Zhai Y, Wang L, Ma P, et al. Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV–Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae012

BibTeX
@article{Wang2024,
  author = {Wang, Ran and Sun, Lijun and Wang, Xi and Zhai, Yuanyi and Wang, Lijing and Ma, Ping and Wu, Cuisong and Zhou, Yingquan and Chen, Renfang and Wang, Rugang and Zhang, Fengchi and Hua, Wei and Li, Aixin and Xia, Wei and Gao, Yue and Li, Rui and Lv, Shiyun and Shao, Ying and Cao, Yu and Zhang, Tong and Wu, Hao and Cai, Chao and Dai, Lili},
  title = {Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV–Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae012}
}
Kostenlos starten →